Product Reports Resources Pricing Login Book a demo

Intellia Therapeutics

Biotech & Life Sciences · Cambridge, United States · Founded 2014 · IPO 2016

A leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases

Valuation $1.20B
Revenue $59M

Investors

8 investors on Intellia Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 4 investors entered at this stage
Series B+ 4 investors entered at this stage
OrbiMed
University of California
Berkeley
Foresite Capital

Global footprint

Where Intellia Therapeutics has talent and traffic

Workforce by country
5 countries with
team presence
🇺🇸 United States98.7%
🇦🇷 Argentina0.6%
🇪🇸 Spain0.3%
🇬🇧 United Kingdom0.3%
🇩🇪 Germany0.3%
5 countries shown
Web traffic by country
41K monthly visits
across markets
🇺🇸 United States49.5%
🇩🇪 Germany9.5%
🇨🇦 Canada7.6%
🇬🇧 United Kingdom6.3%
🇮🇳 India5.6%
Top 5 markets shown

Talent graph

The shape of Intellia Therapeutics's talent

Dealroom maps Intellia Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

9 standout operatorsDealroom-flagged across the org
3 AI specialistsincl. 1 core researchers
504 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Intellia Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$60M patent portfolio · 75 active families

Estimated portfolio value
$60M
5.0% of market cap · 39.7× smaller than top peer Illumina ($2.4B)
75 active patent families
Where Intellia Therapeutics innovates BioinformaticsCellCell biologyCell therapyGene

Where Intellia Therapeutics concentrates vs peers

Each axis is a top-10 topic across Intellia Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Intellia Therapeutics's 3 investments and acquisitions.

Every disclosed deal where Intellia Therapeutics appeared as a backer or acquirer, 2021–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across Intellia Therapeutics's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Intellia Therapeutics deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Intellia Therapeutics's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        3 of 3 deals

        Market sentiment

        What the market is saying about Intellia Therapeutics

        An AI-synthesized read of the highest-engagement posts about Intellia Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Intellia Therapeutics on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.